Pacira BioSciences (PCRX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Pacira BioSciences

NasdaqGS•Healthcare•Drug Manufacturers - Specialty & Generic

$25.36+0.20(0.01%)Pre-market

Market Cap

$943.73M

P/E

64.5x

P/S

1.3x

P/B

1.4x

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.

How this company scores

GoodMetricSide Score: 70/100

Strongest: Cash & Earnings Quality (25/25); weakest: Profitability (10/25).

Profitability10/25

Growth21/25

Balance Sheet & Red Flags14/25

Cash & Earnings Quality25/25

Strengths

Rising free cash flowRising earningsCash-backed earningsConsistent free cash flow

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 64.5x5y range 19.2x – 203.9x

Currently near its 14-quarter median.

P/S · 1.3x5y range 1.0x – 5.9x

Currently below its 20-quarter median.

P/B · 1.4x5y range 0.9x – 4.8x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Price & Volume

Market Cap $943.73M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $746.16M
Q. Revenue: $192.40M
TTM EBITDA: $105.03M
TTM Op. Income: $19.87M
Q. Op. Income: $4.27M
TTM Net Income: $14.64M
Q. Net Income: $4.65M
EPS: $0.12
Shares Out.: $39.46M

$746.16M in TTM revenue grew 6.3% YoY, reaching $192.40M last quarter. TTM EBITDA of $105.03M and TTM operating income of $19.87M show growth is flowing through to the bottom line. TTM net income of $14.64M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 77.0%
EBITDA Margin: 13.3%
Op. Margin: 2.2%
Net Margin: 2.4%

Op. margin of 2.2% is down 2.5% YoY — costs are rising relative to revenue. Net margin at 2.4% and gross margin of 77.0% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 53% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 64.5x
P/S Ratio: 1.3x
P/B Ratio: 1.4x

At 64.5x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 1.3x and P/B of 1.4x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is up 0% — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.24B
Cash: $205.88M
Long-Term Debt: $363.12M
Book Value: $671.98M
D/E Ratio: 0.5
Debt/EBITDA: 14.2

With $1.24B in assets and $363.12M in long-term debt, D/E is 0.5and book value is $671.98M — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is down 29% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $57.46M
TTM Free Cash Flow: $179.51M
FCF Margin: 24.1%
FCF / Net Income: 12.3

TTM FCF of $179.51M on $57.46M in operating cash flow. The FCF / Net Income ratio of 12.3x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 53% — an improving trend.